Tag: cancer biologics market trends

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Cancer biologics Market Expected to Grow Between 2025 And 2029?

The market size for cancer biologics has experienced swift growth in the past few years. It is projected to increase from $106.2 billion in 2024 to $117.03 billion in 2025, boasting a compound annual growth rate (CAGR) of 10.2%. The significant growth during the historic period is deduced from the surge in cancer cases, escalated consciousness about cancer biologics, advances in the efficiency and safety of cancer biologics, the sanction of novel cancer biologics, and an expanding endorsement for combination therapy.

What Growth Rate Is Anticipated for the Cancer biologics Market in the Coming Years?

In the coming years, the cancer biologics market is projected to experience robust expansion. The market is anticipated to increase to a value of $168.75 billion in 2029, with a compound annual growth rate (CAGR) of 9.6%. This significant growth during the forecast period can be credited to numerous factors such as broadening indications, combination therapies, real-world proof, gene, and cell therapies. The forecast framework also indicates key trends including progress in biotechnology, personalization of cancer biologics, biobetters and biosimilars, patient support services, and companion diagnostics.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp

Who Are the Leading Companies in the Cancer biologics Market?

Major companies operating in the cancer biologics market include AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.

What Are the Key Drivers of the Cancer biologics Market?

The increasing incidence of chronic ailments is a significant propellant for the growth of the cancer biologics market. These are diseases with a prolonged duration, negatively impacting individuals with disabilities. Cancer ranks high among these chronic diseases. Common types of cancers include breast, lung and bronchus, prostate, colon and rectum, skin melanoma, bladder, non-Hodgkin lymphoma, kidney and renal pelvis, endometrial, leukemia, pancreatic, thyroid, and liver cancers. As per data released by the US-based public health agency Centers for Disease Control and Prevention (CDC) in February 2024, an escalating number of Americans are contending with multiple chronic conditions—42% with two or more, and 12% with five or more. Accordingly, this increasing frequency of chronic diseases is projected to fuel the growth of the cancer biologics market in the foreseeable future.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2563&type=smp

What Are the Key Market Segments in the Cancer biologics Industry?

The cancer biologics market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types

2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications

3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines

3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy

4) By Other Types: Cytokines, Growth Factors, Fusion Proteins

What Are the Latest Trends in the Cancer biologics Market?

Businesses operating in the cancer biologics market are innovating predictive biomarkers that assist doctors in determining their patients’ treatments by leveraging physiological biomarkers to forecast performance. These predictive biomarkers evaluate tumor progression in patients by inspecting the key causative elements, considering that each patient’s cancer cause varies. Furthermore, these biomarkers are instrumental not just in early cancer diagnosis but also in choosing the most cost-efficient treatment plans, particularly for biologics rooted in gene therapy.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

What Are the Key Regional Markets in the Cancer biologics Industry?

The countries covered in the cancer biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2563

This Report Delivers Insight On:

1. How big is the cancer biologics market, and how is it changing globally?

2. Who are the major companies in the cancer biologics market, and how are they performing?

3. What are the key opportunities and risks in the cancer biologics market right now?

4. Which products or customer segments are growing the most in the cancer biologics market?

5. What factors are helping or slowing down the growth of the cancer biologics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the cancer biologics industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What is the Anticipated CAGR of the Cancer biologics Market, and What Factors Will Drive It?#_x000D_

Rapid expansion has been evident in recent years in the cancer biologics market. The market, which will expand from $106.2 billion in 2024 to $117.03 billion in 2025, is expected to grow at a compound annual growth rate (CAGR) of 10.2%. Several factors contributed to this historic period growth, such as the increased prevalence of cancer, heightened awareness of cancer biologics, enhanced efficacy and safety of these biologics, new approvals of cancer biologics, and a broader acceptance of combination therapy._x000D_

_x000D_

In the upcoming years, the size of the cancer biologics market is projected to witness a robust expansion. By 2029, it is estimated to reach a value of $168.75 billion, with a compound annual growth rate (CAGR) of 9.6%. The anticipated growth during the forecast period can be linked to the broader indications, combination treatments, real-world evidence, as well as gene and cell therapies. Key emerging trends during this period comprise biotechnological advancements, personalized cancer biologics, bio-better products, biosimilars, patient support services, and companion diagnostic methods._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp_x000D_

_x000D_

#Which Primay Drivers Are Accelerating Growth in the Cancer biologics Market?#_x000D_

The cancer biologics market’s development is primarily propelled by the increasing incidence of chronic illnesses. These are conditions that endure for an extended time and have a detrimental impact on the health of individuals with disabilities, with cancer being a frequent chronic disease example. The most frequently diagnosed cancers include breast cancer, lung and bronchus cancer, prostate cancer, colon, and rectum cancer, skin melanoma, bladder cancer, non-Hodgkin lymphoma, kidney, and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. For instance, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, released reports in February 2024 indicating a growing trend of Americans managing multiple chronic conditions. Notably, 42% of them are managing at least two, and 12% handle five or more. Hence, the increasing occurrence of chronic diseases is anticipated to fuel the development of the cancer biologics market in the foreseeable future._x000D_

_x000D_

#Which Primary Segments of the Cancer biologics Market Are Driving Growth and Industry Transformations?#_x000D_

The cancer biologics market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types_x000D_

2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications_x000D_

3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels_x000D_

_x000D_

Subsegments:_x000D_

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies_x000D_

2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines_x000D_

3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy_x000D_

4) By Other Types: Cytokines, Growth Factors, Fusion Proteins_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=2563&type=smp_x000D_

_x000D_

#Which Regions Are Key Players in the Growth of the Cancer biologics Market?#_x000D_

The countries covered in the cancer biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada._x000D_

_x000D_

#What Are the Most Significant Market Trends in the Cancer biologics Market?#_x000D_

Firms in the cancer biologics market are advancing predictive biomarkers that guide doctors in determining the appropriate treatments for their patients using physiological biomarkers to predict outcomes. These predictive biomarkers examine tumor growth in patients by scrutinizing the primary causative factors, given that the etiology of cancer varies among individuals. Furthermore, these biomarkers are instrumental not just in early cancer detection but also in selecting the most economically viable treatment plans, particularly for biologics employing gene therapy._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report_x000D_

_x000D_

#What Parameters Are Used to Define the Cancer biologics Market?#_x000D_

Cancer biologics refer to a substance used in the prevention, detection, or treatment of cancer and other disorders that are created from a living creature or its byproducts. Immunoglobulins, interleukins, and vaccinations are examples of biologic agents. A form of cancer treatment known as biological therapy employs the body’s immune system to eradicate cancer cells._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2563_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Are the Primary Drivers Supporting the Market Growth of theCancer biologics Market?

The growing prevalence of chronic diseases is one of the primary factors influencing the expansion of the cancer biologics market. Chronic conditions, which persist over a long period, affect people’s health and often result in disabilities. Cancer is one of the most common chronic diseases, including types such as breast, lung, prostate, and colorectal cancer. A report from the Centers for Disease Control and Prevention (CDC) in February 2024 revealed that 42% of Americans have two or more chronic conditions, and 12% have five or more. This rising incidence of chronic diseases is expected to spur the growth of the cancer biologics market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp

How Will the Growth Rate of theCancer biologics Market Impact Industry Trends by 2034?

The cancer biologics market size has grown rapidly in recent years. It will grow from $106.2 billion in 2024 to $117.03 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth is attributed to the rising incidence of cancer, increasing awareness of biologics, improvements in treatment efficacy and safety, and the approval of new biologics.

The cancer biologics market is expected to grow at a solid pace, reaching $168.75 billion by 2029 at a CAGR of 9.6%. The growth is supported by expanding indications, combination therapies, real-world evidence, and the development of gene and cell therapies. Key trends will include advances in biotechnology, personalized cancer biologics, biobetters, biosimilars, patient support services, and companion diagnostics.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2563

Which Upcoming Market Trends and Innovations Are Set to Influence theCancer biologics Market’s Path Forward?

Companies in the cancer biologics market are working on predictive biomarkers that assist doctors in selecting personalized therapies. These biomarkers analyze cancer origins and help forecast treatment response, offering insights into early detection and cost-effective therapies, especially for biologics and gene therapies.

Who Are the Major Industry Players Accelerating Growth in theCancer biologics Market?

Major companies operating in the cancer biologics market include AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Which Primary Segments of the Cancer biologics Market Are Driving Growth and Industry Transformations?

The cancer biologics market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types

2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications

3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines

3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy

4) By Other Types: Cytokines, Growth Factors, Fusion Proteins

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=2563&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of theCancer biologics Market?# Market?

The countries covered in the cancer biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Browse Through More Reports Similar to the Global Cancer biologics Market 2025, By The Business Research Company:

Cancer Immunotherapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Cervical Cancer Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cervical-cancer-diagnostics-global-market-report

Breast Cancer Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the cancer biologics market?

In the last few years, there has been a substantial expansion in the size of the cancer biologics market. It is anticipated to grow from $106.2 billion in 2024 to $117.03 billion in 2025, seeing a compound annual growth rate (CAGR) of 10.2%. Factors such as a rise in the occurrence of cancer, heightened awareness surrounding cancer biologics, enhanced efficacy and safety, approval of new cancer biologic treatments, and a growing preference towards combination therapy have contributed to historical growth patterns.

What will be the cancer biologics market size in the future?

Over the coming years, the cancer biologics market is projected to experience significant expansion, reaching a value of $168.75 billion in 2029 with a compound annual growth rate (CAGR) of 9.6%. This anticipated growth during the forecast period is largely due to factors such as the broadening of indications, the introduction of combination therapies, the use of real-world evidence, and the development of gene and cell therapies. The period is also expected to showcase predominant trends such as the progress in biotechnology, individualized cancer biologics, biobetters, biosimilars, enhancements in patient support services, and the rise in companion diagnostics.

Get your cancer biologics market report here!

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp

What main drivers are fueling expansion in the cancer biologics market?

The escalating occurrence of chronic ailments is a prominent factor contributing to the growth of the cancer biologics market. Chronic diseases are enduring health conditions that compromise the wellbeing of disabled individuals, and cancer sits amongst the most prevalent chronic ailments. Top chronic diseases include breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. For example, data released by the Centers for Disease Control and Prevention (CDC), an American public health institution, in February 2024 indicated an upward trend in Americans coping with multiple chronic diseases, with 42% managing at least two, and 12% handling five or more. Hence, the increasing incidence of chronic diseases is predicted to propel the cancer biologics market expansion in the ensuing years.

What key areas define the segmentation of the global cancer biologics market?

The cancer biologics market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types

2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications

3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines

3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy

4) By Other Types: Cytokines, Growth Factors, Fusion Proteins

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp

Who are the dominant players expanding their reach in the cancer biologics market?

Major companies operating in the cancer biologics market include AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.

How are evolving market trends shaping cancer biologics Strategies?

Firms operating in the cancer biologics sector are advancing predictive biomarkers used by doctors to determine patient treatment plans, by leveraging physiological biomarkers for performance forecasting. Predictive biomarkers investigate tumor advancement in patients by examining the key causal factors, given that each patient’s cancer etiology varies. Importantly, these biomarkers contribute not only to the early identification of cancer, but also assist in choosing the most cost-beneficial treatment strategies, particularly for biologics derived from gene therapy.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2563

Which regions are emerging as leaders in the cancer biologics market?

North America was the largest region in the cancer biologics market in 2024. The Middle East is expected to be the fastest-growing region in the global cancer biologics market share during the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Cancer Immunotherapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Cervical Cancer Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cervical-cancer-diagnostics-global-market-report

Breast Cancer Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What CAGR is Anticipated for the Cancer biologics Market During the Forecast Period, and Why?

In the last few years, there has been a substantial expansion in the size of the cancer biologics market. It is anticipated to grow from $106.2 billion in 2024 to $117.03 billion in 2025, seeing a compound annual growth rate (CAGR) of 10.2%. Factors such as a rise in the occurrence of cancer, heightened awareness surrounding cancer biologics, enhanced efficacy and safety, approval of new cancer biologic treatments, and a growing preference towards combination therapy have contributed to historical growth patterns.

Over the coming years, the cancer biologics market is projected to experience significant expansion, reaching a value of $168.75 billion in 2029 with a compound annual growth rate (CAGR) of 9.6%. This anticipated growth during the forecast period is largely due to factors such as the broadening of indications, the introduction of combination therapies, the use of real-world evidence, and the development of gene and cell therapies. The period is also expected to showcase predominant trends such as the progress in biotechnology, individualized cancer biologics, biobetters, biosimilars, enhancements in patient support services, and the rise in companion diagnostics.

Which Macro and Microeconomic Factors Are Accelerating the Growth of the Cancer biologics Market?

The escalating occurrence of chronic ailments is a prominent factor contributing to the growth of the cancer biologics market. Chronic diseases are enduring health conditions that compromise the wellbeing of disabled individuals, and cancer sits amongst the most prevalent chronic ailments. Top chronic diseases include breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. For example, data released by the Centers for Disease Control and Prevention (CDC), an American public health institution, in February 2024 indicated an upward trend in Americans coping with multiple chronic diseases, with 42% managing at least two, and 12% handling five or more. Hence, the increasing incidence of chronic diseases is predicted to propel the cancer biologics market expansion in the ensuing years.

Request Your Free Cancer biologics Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp

Which Companies Are Poised to Shape the Future of the Cancer biologics Market?

Major companies operating in the cancer biologics market include AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.

What Are the Latest Trends Leading to Disruption in the Cancer biologics Market?

Firms operating in the cancer biologics sector are advancing predictive biomarkers used by doctors to determine patient treatment plans, by leveraging physiological biomarkers for performance forecasting. Predictive biomarkers investigate tumor advancement in patients by examining the key causal factors, given that each patient’s cancer etiology varies. Importantly, these biomarkers contribute not only to the early identification of cancer, but also assist in choosing the most cost-beneficial treatment strategies, particularly for biologics derived from gene therapy.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

What Major Market Segments Define the Scope and Growth of the Cancer biologics Market?

The cancer biologics market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types

2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications

3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines

3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy

4) By Other Types: Cytokines, Growth Factors, Fusion Proteins

What Regions Are Contributing Significantly to the Growth of the Cancer biologics Market?

The countries covered in the cancer biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

How Is the Scope and Reach of the Cancer biologics Market Defined?

Cancer biologics refer to a substance used in the prevention, detection, or treatment of cancer and other disorders that are created from a living creature or its byproducts. Immunoglobulins, interleukins, and vaccinations are examples of biologic agents. A form of cancer treatment known as biological therapy employs the body’s immune system to eradicate cancer cells.

Browse Through More Similar Reports By The Business Research Company:

Cancer Immunotherapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Cervical Cancer Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cervical-cancer-diagnostics-global-market-report

Breast Cancer Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: